

ATTORNEY DOCKET NO.: INEX.P-006-2 PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Semple

Serial No.:

10/086,477

Confirmation No.:

3225

Filed:

March 1, 2002

Title:

Compositions for stimulating cytokine secretion and inducing an immune

response

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents and Trademarks

Washington, D.C. 20231

Sir:


Applicant requests that the references listed on Substitute for Form PTO-1449, which is enclosed, be made of record in the Patent Office file relating to the above-captioned application. Copies of the references are provided herewith. No fee is believed to be due with this paper as we have not received an action on the merits.

Respectfully submitted,

OPPEDAHL & LARSON LLP	
Maura I darsol	_
Marina T. Larson, Ph.D.	
Reg. No. 32,038	
P.O. Box 5068	
Dillon, Co. 80435-5068	
Phone: 970-468-6600	

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this paper and the attachments named herein are being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231 on			
July 11, 2002	,		
7-11-02	ori Douth		
Date of signature	Lori South		



Application No.:

10/086,477

Applicant:

Semple

Filing Date:

3/1/2002

Conf. No.:

3225

Title: Compositions for stimulating

cytokine secretion and

inducing an immune response

Attorney Docket No.: INEX.P-006-2

Page 1 of 3

U.S. PATENT DOCUMENTS

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
	5,552,155	Bailey, et al.	09/03/1996
	5,264,618	Felgner, et al.	11/23/1993
	5,595,756	Bally, et al.	01/21/1997
	6,194,388	Krieg, et al.	02/27/2001
	6,207,646	Krieg, et al.	03/27/2001
	6,218,371	Krieg, et al.	04/17/2001
	5,703,055	Felgner, et al.	12/30 /1997
	5,976,567	Wheeler, et al.	11/02/1999

FOREIGN PATENT DOCUMENTS

Examiners Initials	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
	WO 94/05333	ISIS Pharmaceuticals, Inc.	3/17/1994
	WO 97/07784	Board of Regents, The University of Texas System	03/06/1997
	WO 96/18372	Genzyme Corporation	06/20/1996
	WO 97/46223	Genzyme Corporation	12/11/1997
	WO 95/27478	The Liposome Company, Inc.	10/19/1995
	WO 97/46671	The University of British Columbia	12/11/1997
	WO 96/40964	Inex Pharmaceuticals Corporation	12/19/1996
	WO 96/10391	The University of British Columbia	04/11/1996
	WO 96/02555	The University of Iowa Research Foundation	02/01/1996
	WO 98/18810	The University of Iowa Research Foundation	05/07/1998
	WO 98/40100	Ottawa Civic Loeb Research Institute	09/17/1998



Substitute for form 1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.:

10/086,477

Applicant:

Semple

Filing Date:

3/1/2002

Conf. No.:

3225

Title: Compositions for stimulating

cytokine secretion and

inducing an immune response

Attorney Docket No.: INEX.P-006-2

Page 2 of 3

WO 98/55495	Dynavax Technologies Corp.	12/10/1998
 WO 98/51278	Inex Pharmaceuticals Corporation	11/19/1998
WO 94/22468	Anti-cancer, Inc.	10/13/1994
WO 96/10390	Inex Pharmaceuticals Corporation	04/11/1996

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	
	Zelphati, O. et al., "Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet?", Journal of Controlled Release, 41 (1996) pp. 99-119
	McCluskie, et al., "Novel strategies using DNA for the induction of mucosal immunity", Critical Reviews in Immunology, 19: pp. 303-329 (1999)
	Mok, et al., "Stablized plasmid-lipid particles: factors influencing plasmid entrapment and transfection properties", <i>Bjiochimica et Biophysica Acta 1419</i> (1999) pp. 137-150
	Ishii, et al., "Catonic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1", Aids Research and Human Retroviruses, Vol. 13, no. 16, 1997 pp. 1421-1428
	Freimark, et al., "Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes", <i>The Journal of Immunology</i> , pp. 4580-4586 (1998)
	Bei, et al., "The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice", <i>Journal of Immunotherapy</i> , 21(3) pp. 159-169, Vol. 21, no. 3 (1998)
	Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs" <i>Molecular Membrane Biology</i> , Vol. 16, No. 1, January 1999 (1999-01), pp. 129-140, XP000982197
	Meyer Olivier, et al. "Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides", Journal of Biological Chemistry, Vol. 273, No. 25, June 19, 1998, pp. 15621-15627, XP002160291
	Boggs R.T., et al. "Characterization and modulation of immune stimulation by modified oligonucleotides", Antisense & Nucleic Acid Drug Development, Vol. 7, Ocober 1, 1997, pp. 461-471, XP002053418
	Chu R.S., et al. "CpG Oligodeoxynucleotides Act as Adjuvants that switch on T Helper 1 (TH1) Immunity", Journal of Experimental Medicine, JP, Tokyo, Vol. 186, No. 10, November 1, 1997, pp. 1623-1631, XP002910130



Substitute for form 1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.:

10/086,477

Applicant:

Semple

Filing Date:

3/1/2002

Conf. No.:

3225

Title: Compositions for stimulating

cytokine secretion and

inducing an immune response

Attorney Docket No.: INEX.P-006-2

Page 3of 3

Bramson, et al., "Intravenous administration of stablilized antisense lipid particles (SALP) leads to activation and expansion of liver natural killer cells", <i>Antisense & Nucleic Acid Drug Development</i> , Vol. 10, No. 3, June 2000, pp. 217-224, XP002160292
Whitmore, et al., "LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth", <i>Gene Therapy</i> , Vol. 6, No. 11, November 1999, pp. 1867-1875, XP000982147

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner Signature	Date Considered	